002589 Realcan Pharmaceutical Group
- 3.08
- -0.02-0.65%
Realcan Pharmaceutical Group News
Ruikang Pharmaceutical (002589): Goodwill impairment affects performance adjustment period and forge ahead
Ruikang Pharmaceutical (002589): Q3 performance slightly lower than expected continuous improvement in operating data
Ruikang Pharmaceutical (002589) 2019 mid-report comments: cash flow continues to improve equipment continues to maintain a high growth rate
Ruikang Pharmaceutical (002589): continuous improvement of cash flow equipment and continued rapid growth outside the province
Ruikang Pharmaceutical (002589): significant improvement in operating cash flow during adjustment and integration
Ruikang Pharmaceutical (002589) 2018 Annual Report and 2019 Quarterly Report Reviews: Significant Cash Flow Improvement Towards a New Stage of Connotative Development
Ruikang Pharmaceutical (002589): The trend of improving cash flow is obvious, devices and the province continues to maintain rapid growth
Ruikang Pharmaceutical (002589): the core operating data keep improving at a high rate of revenue growth.
Ruikang Pharmaceutical (002589) comments: employee Stock ownership draft and share Repurchase Plan convey confidence
Ruikang Pharmaceutical (002589) Investment value Analysis report: the national channel layout is coming to an end, integration and efficiency improvement has ushered in the turning point.
瑞康医药(002589)季报点评：收入持续高增长 经营性现金流逐季改善
《医药流通》公司篇之瑞康医药(002589)深度报告：器械整合先行者 全国平台高效协同
瑞康医药(002589)季报点评：Q3单季扣非净利增长29% 经营性现金流大幅转正
瑞康医药(002589)三季报点评：业绩快速增长 三季度现金流大幅改善
瑞康医药(002589)三季报点评：经营现金流大幅改善 供应链金融稳步推进
瑞康医药(002589)三季报点评：业绩表现靓丽 延续快速增长态势
瑞康医药(002589)季报点评：强化内部管控 经营性现金流继续实现大幅改善
瑞康医药(002589)中报点评：实现全国直销渠道建设 器械业务持续高增长
瑞康医药(002589)中报点评：收入增速提升 单季度现金流改善
瑞康医药(002589)中报点评：器械、省外业务高速增长 Q2现金流同比改善
Analysis
Price Target
No Data
No Data